DuPont de Nemours, Inc.

The Company's measure of profit/loss for segment reporting purposes is Operating EBITDA as this is the manner in which the Company's chief operating decision maker ("CODM") assesses performance and allocates resources. The Company defines Operating EBITDA as earnings (i.e., "Income from continuing operations before income taxes") before interest, depreciation, amortization, non-operating pension / other post-employment benefits ("OPEB") / charges, and foreign exchange gains / losses, excluding costs related to activities the Company will or continues to undertake post-closing of the Aramids Divestiture and Electronics Separation, and for which it is or will be reimbursed ("Future Reimbursable Indirect Costs"), environmental remediation costs, including certain investigate, remediate and restoration costs, associated with discontinued or divested operations, businesses or product lines ("Corporate DDOB Remediation Costs"), and is adjusted for significant items.

Healthcare & Water Technologies

1. Organic sales (which includes both volume and selling price impacts), is defined as the change in net sales, absent the impacts from currency and portfolio. DuPont believes this information is useful to investors and management in understanding ongoing operations and in analysis of ongoing operating trends.

Healthcare & Water Technologies net sales were $856 million for the three months ended June 30, 2026, up 5 percent compared to $817 million for the three months ended June 30, 2025. Net sales increased due to 4 percent organic sales growth and a 1 percent increase from favorable currency impacts. Organic sales growth in Healthcare & Water Technologies was driven by broad-based volume growth led by personal protection and biopharma in Healthcare Technologies and continued strength in industrial water and semiconductor markets within Water Technologies, partially offset by weakness in the Middle East. The favorable currency impact reflected the weakening of the U.S. dollar compared to the Euro.

Operating EBITDA was $258 million for the three months ended June 30, 2026, up 4 percent compared with $248 million for the three months ended June 30, 2025, primarily due to the impact of organic growth and manufacturing productivity, partially offset by growth investments.

Healthcare & Water Technologies net sales were $1,662 million for the six months ended June 30, 2026, up 5 percent compared to $1,580 million for the six months ended June 30, 2025. Net sales increased due to 3 percent organic sales growth and a 2 percent increase from favorable currency impacts. Organic sales growth in Healthcare & Water Technologies was driven by organic sales increases within Healthcare Technologies. Within Healthcare Technologies, organic sales growth was driven by broad-based volume growth in medical packaging and biopharma end-markets. Organic sales were about flat in Water Technologies as strength in industrial water and semiconductor markets was offset by weakness in the Middle East. The favorable currency impact reflected the weakening of the U.S. dollar compared to the Euro.

Operating EBITDA was $502 million for the six months ended June 30, 2026, up 7 percent compared with $471 million for the six months ended June 30, 2025, primarily due to the impact of organic growth and manufacturing productivity.

Diversified Industrials

1. Organic sales (which includes both volume and selling price impacts), is defined as the change in net sales, absent the impacts from currency and portfolio. DuPont believes this information is useful to investors and management in understanding ongoing operations and in analysis of ongoing operating trends.

Diversified Industrials net sales were $963 million for the three months ended June 30, 2026, up 3 percent from $932 million for the three months ended June 30, 2025. Net sales increased due to 3 percent organic sales growth. Within Industrial Technologies, organic sales growth was driven by strength in aerospace markets coupled with growth in electric vehicle applications. In Building Technologies, organic sales growth was led by growth in residential and non-residential construction markets.

Operating EBITDA was $213 million for the three months ended June 30, 2026, up 7 percent compared with $199 million for the three months ended June 30, 2025, primarily driven by organic growth, favorable mix, and manufacturing productivity.

Diversified Industrials net sales were $1,838 million for the six months ended June 30, 2026, up 3 percent from $1,781 million for the six months ended June 30, 2025. The increase in net sales was driven by 2 percent organic sales growth and a 1 percent increase from favorable currency impacts. In Industrial Technologies, organic sales growth was driven by strength in aerospace markets. Organic sales growth in Building Technologies was flat. The favorable currency impact reflected the weakening of the U.S. dollar compared to the Euro.

Operating EBITDA was $413 million for the six months ended June 30, 2026, up 8 percent compared with $384 million for the six months ended June 30, 2025, primarily driven by organic growth, manufacturing productivity and favorable mix.